Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of bi- versus triplet chemotherapy plus KRAS-guided targeted therapy for initially unresectable liver metastases from metastatic colorectal cancer
2009-012813-22Phase 2Active
- Sponsor
- Unicancer
- Start
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, irinotecan, folinic acid, fluorouracil, cetuximab and 1 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Unicancer. Primary endpoint: Resection rate of liver metastases. Started Jul 2010; status: active.
02
Drugs
oxaliplatinirinotecanfolinic acidfluorouracilcetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-012813-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012813-22.